Hopital Avicenne — Clinical Trial Site

37 Registered trials

13 Currently recruiting

Organisation

Hopital Avicenne

Location

Bobigny Cedex, France

Identifier

ORG-100028408

Address

125 Rue De Stalingrad, 93009, France

Departments

#2059: Service de Dermatologie
#2302:Hématologie Clinique
201:Hématologie Clinique
2406: Obesity Nutrition
Clinical Research
Département de dermatologie
Department of hepatology
Department of Pulmonology
dermatologie
Dermatology
Emergency
FR30008 Hématologie Clinique
Gastroenterologist
Hématologie
Hematology
Hepatogastro-enterology
hepatogastroenterologie
Infectious disease
Infectious diseases
Internal Medecine Unit
Médecine interne
Medical Oncology
Medical Thoracic Oncology
N/A
Pneumology
Service d’hématologie clinique
Service d’Hepatologie
Service de Pneumologie
Service des Maladies Infectieuses et Tropicales

Clinical trials at this site (37)

Search interface

A study to assess the efficacy and safety of OATD-01 for the treatment of active pulmonary sarcoidosis. Not authorised

2023-506642-23-00 Active Pulmonary Sarcoidosis 4
A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Unknown

2022-502779-40-99 Primary prevention of atherosclerotic cardiovascular di 5
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis Recruiting

2023-503699-25-00 Progressive Pulmonary Fibrosis 5 2024-07-15
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis Recruiting

2023-503697-21-01 Idiopathic pulmonary fibrosis 5 2024-06-24
Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome Recruiting

2023-507528-21-00 Gorlin Syndrome 5 2024-05-23
AKAPI: Amikacin Liposome Inhalation Suspension for treatment of Mycobacterium xenopi pulmonary infection: A prospective controlled open-labe… Recruiting

2023-506843-40-00 Mycobacterium xenopi pulmonary infection 5 2025-10-29
Interventional, multicenter, open-label, randomized, non-comparative trial evaluating the safety, in terms of HBV virological control, of 2 … Recruiting

2023-508634-34-00 co-infected with the HIV-1 and HBV viruses 4 2025-05-14
MICROBIOTA MODIFICATION FOR IMMUNO-ONCOLOGY IN HEPATOCELLULAR CARCINOMA - “MOTHER” Recruiting

2023-508201-25-00 Hepatocellular carcinoma 4 2025-03-12
A study to assess the efficacy and safety of OATD-01 for the treatment of active pulmonary sarcoidosis. Recruiting

2023-506642-23-01 Active Pulmonary Sarcoidosis 4 2024-08-28
Amoxicillin alone versus amoxicillin/clavulanate for community-acquired pneumonia in patients aged 65 years or older, and hospitalized in a … Recruiting

2023-503645-63-00 Patients aged 65 years or older, hospitalized in a non- 5 2024-04-25
A trial to learn if odronextamab combined with lenalidomide is safe and works better than rituximab combined with lenalidomide in adult part… Recruiting

2022-503092-28-00 Relapsed/Refractory Follicular Lymphoma 5 2024-01-08
EvER-ILD 2: Evaluation of Efficacy and safety of Rituximab in patients with progressive Interstitial Lung Disease (ILD) with inflammatory co… Recruiting

2022-501335-16-00 Interstitial lung disease 10 2023-01-16
CPX-351 versus intensive chemotherapy in patients with de novo intermediate or adverse risk AML stratified by genomics Recruiting

2022-500295-60-00 Acute Myeloid Leukemia 4 2022-09-15
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Patients With Stage III Unresectabl… Recruiting

2023-506891-28-00 The target population of interest in this study is part 5 2022-05-02
52 weeks double-blind, double-dummy, randomized placebo-controlled trial to evaluate safety, efficacy and tolerability of remibrutinib in co… Ended

2022-502161-19-00 Chronic Spontaneous Urticaria 5 2024-03-12
SIERRA: Durvalumab and Tremelimumab as First Line Treatment in Participants with Advanced Hepatocellular Carcinoma Ended

2022-502012-37-00 Advanced Hepatocellular Carcinoma 5 2023-10-06
A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Ended

2022-502779-40-00 Primary prevention of atherosclerotic cardiovascular di 5 2023-09-04
A trial to see if the combination of fianlimab with cemiplimab works better than pembrolizumab for preventing or delaying melanoma from com… Ended

2022-501576-25-00 Melanoma 5 2023-07-07
A Registry Study of Treatment With Bulevirtide in Participants With Chronic Hepatitis D Infection Ended

2022-501901-10-00 Chronic Hepatitis D Infection 6 2023-02-06
A study of tucatinib versus placebo in combination with pertuzumab and trastuzumab for subjects with advanced or metastatic HER2+ breast can… Ended

2023-503826-37-00 Unresectable locally-advanced or metastatic HER2+ breas 5 2022-02-11
Phase Ib/III Study of Capivasertib + CDK4/6 Inhibitors + Fulvestrant as Treatment for Advanced/Metastatic HR+/HER2-Breast Cancer (CAPItello-… Ended

2023-504997-39-00 Hormone Receptor-Positive and Human Epidermal Growth Fa 5 2021-06-14
A study comparing current available therapies with imetelstat for the treatment of intermediate-2 or high-risk MF who are not responding to … Ended

2023-509120-17-00 Myelofibrosis 5 2021-04-12
A Phase 3 Randomized Study of Loncastuximab Tesirine Combined with Rituximab Versus Immunochemotherapy in Patients with Relapsed or Refracto… Ended

2023-503916-33-00 Diffuse Large B-Cell Lymphoma (DLBCL) 5 2021-03-24
HOVON 156 AML: Treatment for acute myeloid leukemia (AML) or myelodysplastic syndrome with a FLT3 mutation with gilteritinib or midostaurin … Ended

2022-502478-18-00 Acute Myeloid Leukemia (AML) 4 2019-12-20